An Open-label, Single-dose Study to Assess the Safety, Tolerability and Pharmacokinetic Properties of BELVIQ in Obese Adolescent Subjects Ages 12-17 (Inclusive)
Phase of Trial: Phase I
Latest Information Update: 18 Sep 2019
Price : $35 *
At a glance
- Drugs Lorcaserin (Primary)
- Indications Obesity
- Focus Pharmacokinetics
- Sponsors Arena Pharmaceuticals; Eisai Inc
- 31 Mar 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 22 Jan 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
- 07 Jan 2014 New trial record